Company / Capital Expenditures
Oruka Therapeutics, Inc. Capital Expenditures History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$189.0K
FY2024
5-year range
$0 / $189.0K
FY2020-FY2024
Trend
-
vs FY2023
Sector context
#159 of 194
Health Care
What the data says
Oruka Therapeutics, Inc.'s capital expenditures of $189,000 is lower than 82% of companies in the Health Care sector (FY2024). Capital Expenditures has fluctuated over the past 10 years, ranging from $0 in FY2023 to $189,000 in FY2024.
Based on SEC 10-K filings.
$189,000 in FY2024 with a 5-year CAGR of +116.2%.
Improved from $43,000 to $189,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +115.1%
- 5-Year CAGR
- +116.2%
- 10-Year CAGR
- -
Sector benchmark
Bottom 18% in Health CareTop 82% of 194This company $189.0K Sector average $117.5M
▼
-99.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +116.2%, indicating consistent growth.
- Ranks #159 out of 194 companies in the Health Care sector.
- Lowest capital expenditures in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $189.0K | - |
| FY2023 | $0 | -100.0% |
| FY2022 | $43.0K | +126.3% |
| FY2021 | $19.0K | +375.0% |
| FY2020 | $4.0K | +0.0% |
| FY2019 | $4.0K | +33.3% |
| FY2018 | $3.0K | -75.0% |
| FY2017 | $12.0K | +9.1% |
| FY2016 | $11.0K | -42.1% |
| FY2015 | $19.0K | -40.6% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026